ZYMEWORKS INC. COMMON STOCK

NASDAQ: ZYME (Zymeworks Inc.)

最近更新时间: 29 Nov, 9:31AM

26.71

-0.62 (-2.27%)

前收盘价格 27.33
收盘价格 27.45
成交量 430,471
平均成交量 (3个月) 1,115,963
市值 2,022,892,032
价格/销量 (P/S) 14.95
股市价格/股市净资产 (P/B) 6.29
52周波幅
9.03 (-66%) — 28.49 (6%)
利润日期 6 Nov 2025
营业毛利率 -121.73%
营业利益率 (TTM) -94.48%
稀释每股收益 (EPS TTM) -1.50
季度收入增长率 (YOY) 170.30%
总债务/股东权益 (D/E MRQ) 5.68%
流动比率 (MRQ) 4.71
营业现金流 (OCF TTM) -75.78 M
杠杆自由现金流 (LFCF TTM) -21.20 M
资产报酬率 (ROA TTM) -13.89%
股东权益报酬率 (ROE TTM) -29.80%

市场趋势

短期 中期
行业 Biotechnology (US) 看涨 混合的
Biotechnology (全球的) 看涨 混合的
股票 Zymeworks Inc. 看涨 看涨

AIStockmoo 评分

-0.1
分析师共识 1.5
内部交易活动 NA
价格波动 -5.0
技术平均移动指标 -1.0
技术振荡指标 4.0
平均 -0.13

相关股票

股票 市值 DY P/E(TTM) P/B
ZYME 2 B - - 6.29
IONS 13 B - - 21.49
RNA 11 B - - 5.73
NUVL 8 B - - 10.04
RYTM 7 B - - 48.92
PTCT 6 B - 9.05 -

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 0.15%
机构持股比例 102.76%
52周波幅
9.03 (-66%) — 28.49 (6%)
目标价格波幅
23.00 (-13%) — 40.00 (49%)
40.00 (B. Riley Securities, 49.76%) 购买
40.00 (Stifel, 49.76%) 购买
32.00 (19.81%)
23.00 (JP Morgan, -13.89%) 购买
平均值 32.00 (19.81%)
总计 5 购买, 1 保留
平均价格@调整类型 22.64
公司 日期 目标价格 调整类型 价格@调整类型
Citizens 03 Dec 2025 32.00 (19.81%) 购买 25.10
B. Riley Securities 21 Nov 2025 40.00 (49.76%) 购买 24.02
10 Oct 2025 30.00 (12.32%) 购买 18.06
Stifel 19 Nov 2025 40.00 (49.76%) 购买 22.60
Wells Fargo 19 Nov 2025 25.00 (-6.40%) 保留 22.60
07 Nov 2025 17.00 (-36.35%) 保留 16.46
HC Wainwright & Co. 18 Nov 2025 32.00 (19.81%) 购买 22.99
14 Oct 2025 26.00 (-2.66%) 购买 18.23
JP Morgan 16 Oct 2025 23.00 (-13.89%) 购买 18.55

该时间范围内无数据。

日期 类型 细节
02 Dec 2025 公告 Zymeworks Announces Participation in Upcoming Conferences
24 Nov 2025 公告 Zymeworks Announces Participation in Upcoming Investor Conferences
18 Nov 2025 公告 Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
18 Nov 2025 公告 Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
18 Nov 2025 公告 Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
18 Nov 2025 公告 Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
17 Nov 2025 公告 Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
17 Nov 2025 公告 Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
06 Nov 2025 公告 Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
28 Oct 2025 公告 Zymeworks Announces Participation in Upcoming Investor Conferences
23 Oct 2025 公告 Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
23 Oct 2025 公告 Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
16 Oct 2025 公告 Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
13 Oct 2025 公告 Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
13 Oct 2025 公告 Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
09 Oct 2025 公告 InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
09 Oct 2025 公告 Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
09 Oct 2025 公告 Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票